Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib.
J
J
Dengler
N
N
von Bubnoff
T
T
Decker
C
C
Peschel
J
J
Duyster
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D001402:B-Lymphocytes / Q000187:drug effects* / Q000378:metabolism; D001549:Benzamides; D002478:Cells, Cultured; D019008:Drug Resistance, Neoplasm; D004359:Drug Therapy, Combination; D000068338:Everolimus; D016044:Fusion Proteins, bcr-abl / Q000235:genetics / Q000378:metabolism*; D000068877:Imatinib Mesylate; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D051379:Mice; D009154:Mutation / Q000235:genetics; D010879:Piperazines / Q000008:administration & dosage; D011743:Pyrimidines / Q000008:administration & dosage; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology
D001549:Benzamides; D007166:Immunosuppressive Agents; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D000068338:Everolimus; D016044:Fusion Proteins, bcr-abl; D020123:Sirolimus